TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00540436
Drug: GSK1325760A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
Study: NCT04640324
Drug: Nutraceutical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
Study: NCT03531437
Drug: 15 µg ethinylestradiol and 60 µg gestodene
Normalized name: gestodene and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04019093
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
Study: NCT03558061
Drug: ALK4290
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK4290 400 mg tablet twice a day
Study: NCT03962283
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Rifaximin four times daily
Study: NCT01300611
Drug: TXA127 300 mcg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, 300 mcg/kg/day for 28 days
Study: NCT01300611
Drug: TXA127 1000 mcg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, 1000 mcg/kg/day for 28 days
Study: NCT01574313
Drug: 0.25mg, fludiazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg of erispan@ (fludiazine), p.o. one dose only.
Study: NCT01574313
Drug: 25mg cephadol@ (diphenidol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg cephadol@ (diphenidol) p.o. one dose only.
Study: NCT01574313
Drug: 200mg kentons@ (tocopherol nicotinate).
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
Study: NCT02306187
Drug: Edirol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
Study: NCT02531035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, before the first meal of the day
Study: NCT00119301
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00119301
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02380352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
Study: NCT02772965
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.
Study: NCT04275986
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
Study: NCT02410902
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Study: NCT04928079
Drug: Anti-Parkinsonian Drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using anti-parkinsonian drugs if needed
Study: NCT02322892
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
Study: NCT01043185
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg orally in the morning and 90 mg in the evening for 1 day
Study: NCT01043185
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg orally in the morning and 120 mg in the evening for 1 day
Study: NCT01043185
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg orally in the morning and 240 mg in the evening for 1 day
Study: NCT01043185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
Study: NCT01838174
Drug: IV methylprednisolone (steroids)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 days of intravenous methylprednisolone followed by 11 days of oral taper
Study: NCT00137436
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
Study: NCT00701727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, once a day, for 7 weeks
Study: NCT02757066
Drug: NPC-15 Granules Higher Dose
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin granule which contains 4 mg melatonin
Study: NCT00210080
Drug: Uridine 5'-Triphosphate (UTP) Solution for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01383395
Drug: simvastatin/cilostazol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02856581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01290172
Drug: Administration of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy.
Study: NCT02218658
Drug: WE941 OD tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04389840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline
Study: NCT01562561
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
Study: NCT00153738
Drug: phytosterol
Normalized name: Phytosterol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04649203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Study: NCT03478319
Drug: ACE-2494 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombination fusion protein
Study: NCT00502307
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: solid oral capsule containing excipients dosed daily for three weeks per month
Study: NCT03121222
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
Study: NCT03284294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo daily for 8 weeks
Study: NCT01968720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04547738
Drug: TB treatment according to national guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
Study: NCT01785433
Drug: Spiriva® Respimat® 5 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01002534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal instillation of placebo matching in appearance with the Vardenafil instillation
Study: NCT01856595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
Study: NCT04346628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match favipiravir administered orally through day 10.
Study: NCT02902016
Drug: GED
Normalized name: Fungederm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
Study: NCT04527562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
Study: NCT00002789
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002789
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02106897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Descriptions
Study: NCT03165721
Drug: SGI-110 (guadecitabine)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
Study: NCT02143362
Drug: Anesthesia maintenance , propofol,remifentanil,cisatracurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg).
Study: NCT00861484
Drug: GSK958108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Tablets 1 mg
Study: NCT00861484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablets
Study: NCT04867135
Drug: Amikacin Sulfate Injection
Normalized name: Amikacin Sulfate Injection
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose and frequency of amikacin was defined by each hospital.
Study: NCT02273440
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02273440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01260246
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo match for 6 months
Study: NCT04240821
Drug: Theophylline ER
Normalized name: Theophylline ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline
Study: NCT00506077
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
Study: NCT02902172
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Study: NCT00525798
Drug: SMC021 Oral calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8mg SMC021 - oral calcitonin, once daily
Study: NCT00525798
Drug: SMC021 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC021 - Placebo, once daily
Study: NCT03062904
Drug: Inhaled Bronchodilators +/- Inhaled Methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations
Study: NCT00228254
Drug: Zinc (12.5 mg/day)
Normalized name: zinc oxide 0.12 MG/MG
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00455260
Drug: hGH-ViaDerm™ System (hGH or somatropin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
Study: NCT02631135
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Study: NCT00375115
Drug: Sambucol
Normalized name: Sambucol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00700687
Drug: PA32540
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin/omeprazole
Study: NCT00700687
Drug: PA32540 and celecoxib
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin/omeprazole and celecoxib
Study: NCT01753076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride) infusion
Study: NCT00700687
Drug: aspirin and [NSAID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin and \[NSAID\]
Study: NCT02389816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT02131948
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray
Study: NCT00995345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02336594
Drug: RDEA3170 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02336594
Drug: RDEA3170 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00679679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet counseling and exercise
Study: NCT02651194
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT03179592
Drug: Ultravist 370Mg I/Ml Solution for Injection
Normalized name: Ultravist 370mg I/ml Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced contrast-volume injection protocols based on patient specific tube voltage.
Study: NCT00652431
Drug: Vytorin + Niaspan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
Study: NCT00300469
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg, daily, 12 weeks
Study: NCT00300469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily, 12 weeks, see Arm Description for placebo information
Study: NCT00368017
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill once a day for 12 weeks
Study: NCT01201798
Drug: Prednisolone acetate 1.0% ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
Study: NCT02207699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 placebo perles given by mouth once
Study: NCT03633227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA matching placebo will be administered per the schedule specified in the arm description.
Study: NCT02426411
Drug: EMA401 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02426411
Drug: EMA401 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02426411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01308320
Drug: fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
Study: NCT02249234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02432287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: there is no other name we used for the placebo
Study: NCT00340678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo corresponding to each dose of losartan.
Study: NCT00610935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular injection
Study: NCT01245426
Drug: GW870086 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhalation
Study: NCT01245426
Drug: GW870086 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhalation
Study: NCT01245426
Drug: GW870086 3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhalation
Study: NCT00533637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate buffer with preservatives
Study: NCT01599754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT01476176
Drug: Experimental paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental paracetamol with caffeine
Study: NCT01476176
Drug: Paracetamol marketed formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed formulation containing caffeine
Study: NCT02766283
Drug: iodinated contrast agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular application
Study: NCT02862561
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study: NCT01721408
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
Study: NCT00683345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.67 ml daily subcutaneously as placebo drug.
Study: NCT01137331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid- applied once daily prior to bed
Study: NCT03977727
Drug: Novolog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
Study: NCT00174993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
Study: NCT02231255
Drug: Sifrol®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00488618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo oral administration, once per day.
Study: NCT01595737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
Study: NCT02781467
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01655823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment acting as control arm
Study: NCT00303108
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 IV on Day 1 of each 28 day cycle
Study: NCT03806985
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: microcrystalline cellulose capsule
Study: NCT02252211
Drug: DS-8895a 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.